<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.10.13/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.10.13/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|10|13|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="doc-num" content="13"/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|10|13" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/10.10.13"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.10.13/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.10.13/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10.10" title="Subtitle 10 LABORATORIES">Subtitle 10 LABORATORIES</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|10|13" data-search-heading="">
                  <span title="Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants">Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|10|13">
              <div class="tuf-authenticate">
                <h1 class="h__title--small" id="/us/md/exec/comar/10.10.13">Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants</h1>
                <section class="line-group annotations">
                  <h2>Administrative History</h2>
                  <p>Effective date:</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.01" title=".01 Purpose.">.01</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.27" title=".27 Sanctions.">.27</a> adopted as an emergency provision effective January 1, 2009 (36:2 Md. R. 97); adopted permanently effective March 23, 2009 (36:6 Md. R. 490)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.02#A" title="">Regulation .02A</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.03#B" title="">Regulation .03B</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.04#B" title="">Regulation .04B</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.06#B" title="">Regulation .06B</a> amended as an emergency provision effective July 1, 2012 (39:15 Md. R. 962); amended permanently effective August 20, 2012 (39:16 Md. R. 1080)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.06#B" title="">Regulation .06B</a> amended effective April 27, 2015 (42:8 Md. R. 608); April 14, 2025 (52:7 Md. R. 321)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.12" title=".12 First-Tier, Supplemental, and Second-Tier Tests.">Regulation .12</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C</a> amended effective August 23, 2021 (48:17 Md. R. 669); April 14, 2025 (52:7 Md. R. 321)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.13" title=".13 Screening Test Blood-Spot Specimens — Collection and Test Requisition.">Regulation .13</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.14" title=".14 Screening Test Blood-Spot Specimens — Procedures, Submission, and Delivery Requirements.">Regulation .14</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.15" title=".15 Test Blood-Spot Specimens — Use, Research, Storage, and Retention.">Regulation .15</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.16" title=".16 Test Records — Retention.">Regulation .16</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.17" title=".17 Testing — First-Tier.">Regulation .17</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.18#B" title="">Regulation .18B</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.20#A" title="">Regulation .20A</a>, C amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.21" title=".21 Quality Assessment and Quality Assurance.">Regulation .21</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.23" title=".23 Reporting Test Results.">Regulation .23</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.24#A" title="">Regulation .24A</a>, D amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.25" title=".25 Reporting System and Communication Software.">Regulation .25</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.26#A" title="">Regulation .26A</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.27#C" title="">Regulation .27C</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <h2>Authority</h2>
                  <p>Health-General Article, §§13-101—13-103, 13-108—13-112, 13-601—13-605, 17-201—17-206, 17-210,<br/>17-211, 17-215, and 17-216, Annotated Code of Maryland</p>
                </section>
                <h2 id="/us/md/exec/comar/10.10.13.01" data-order="|10|10|13|.01|" data-ref-path="10|10|13|.01" class="h__section">.01 Purpose.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#A">A.</span> This chapter, together with <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>, establishes a coordinated Statewide system for the screening of newborn infants in the State for certain hereditary and congenital disorders associated with severe problems of health or development.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B">B.</span> This chapter also protects the public health by ensuring that accurate and reliable newborn screening and diagnostic test results are provided to a newborn infant's health care providers by requiring a medical laboratory performing screening tests, diagnostic tests, or both, on newborn infants for hereditary disorders, congenital disorders, or both, to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B(1)">(1)</span> Operate under reliable procedures and test methods;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B(2)">(2)</span> Employ qualified personnel;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B(3)">(3)</span> Establish and maintain reliable quality control and quality assurance programs; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B(4)">(4)</span> Interact effectively with components of the Department's coordinated Statewide Newborn Screening Program to identify newborn infants who may be at risk for a hereditary or congenital disorder.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.02" data-order="|10|10|13|.02|" data-ref-path="10|10|13|.02" class="h__section">.02 Scope.</h2>
                <p>This chapter:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#A">A.</span> Identifies standards and requirements for a medical laboratory performing screening tests, diagnostic tests, or both, for hereditary and congenital disorders on blood-spot specimens from newborn infants; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B">B.</span> Addresses the following newborn screening and diagnostic tests:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(1)">(1)</span> Screening tests, which are:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(1)(a)">(a)</span> First-tier tests; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(1)(b)">(b)</span> Supplemental tests; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(2)">(2)</span> Diagnostic tests, which are:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(2)(a)">(a)</span> Second-tier tests; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(2)(b)">(b)</span> Supplemental tests.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.03" data-order="|10|10|13|.03|" data-ref-path="10|10|13|.03" class="h__section">.03 Definitions.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(1)">(1)</span> "Abnormal test result" means a first-tier, supplemental, or second-tier test result that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(1)(a)">(a)</span> Falls outside the normal range for the analyte measured; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(1)(b)">(b)</span> Triggers a request for additional testing or is diagnostic for a disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(2)">(2)</span> Allele.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(2)(a)">(a)</span> "Allele" means any one of a series of two or more different forms of a gene or DNA sequence that can exist at a single locus on a chromosome.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(2)(b)">(b)</span> "Allele" includes the gene or DNA sequence for hemoglobin traits and disease states, such as hemoglobin S (HbS) for sickle cell disease.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(3)">(3)</span> "Analyte" means the substance or chemical constituent in blood being measured in a screening test used to detect the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)">(4)</span> Birthing Facility.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)(a)">(a)</span> "Birthing facility" means a facility that provides the antepartum, intrapartum, and postpartum management and care of women and their newborn infants.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)(b)">(b)</span> "Birthing facility" includes a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)(b)(i)">(i)</span> Birthing service that is licensed or accredited as a unit of a hospital; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)(b)(ii)">(ii)</span> Freestanding birthing center as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.05.02.01#B" title="">COMAR 10.05.02.01B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)">(5)</span> Blood-Spot Specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(a)">(a)</span> “Blood-spot specimen” means a whole-blood specimen collected from a newborn infant’s heel and applied to the designated area on a blood-spot collection test requisition card for the purpose of performing screening tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(b)">(b)</span> “Blood-spot specimen” includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(b)(i)">(i)</span> The first screening blood-spot specimen collected from a newborn infant, usually in the birthing facility or other place where the newborn infant was born, within 48 hours after the newborn infant’s birth;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(b)(ii)">(ii)</span> The second screening blood-spot specimen collected from a newborn infant, usually collected when the newborn infant is between 10 and 14 days of age; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(b)(iii)">(iii)</span> A blood-spot specimen collected subsequent to a blood-spot specimen specified in §B(5)(b)(i) and (ii) of this regulation as required to meet the medical needs and condition of the newborn infant and any additional specific screening blood-spot specimen collection and screening test requirements of this chapter and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(6)">(6)</span> "Borderline result" means a screening test result that is at or near the established cut-off level for a particular analyte.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(7)">(7)</span> "CLIA" means the federal Clinical Laboratory Improvement Amendments of 1988.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)">(8)</span> Congenital Disorder.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)(a)">(a)</span> "Congenital disorder" means a significant structural or functional abnormality of the body that is present at birth.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)(b)">(b)</span> "Congenital disorder" does not include a condition that results from:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)(b)(i)">(i)</span> An intrauterine infection; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)(b)(ii)">(ii)</span> A birth injury.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(9)">(9)</span> "Council" means the State Advisory Council on Hereditary and Congenital Disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(10)">(10)</span> “Courier” means an entity employed by a person to convey a blood-spot specimen from the site of blood-spot specimen collection to the laboratory where the blood-spot specimen will be tested.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(11)">(11)</span> "Cut-off level" means a pre-determined, measurable value established for an analyte detected by a screening test, where that value is used to determine when a newborn infant's test result is normal, borderline, or abnormal.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(12)">(12)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(13)">(13)</span> "Diagnostic test" means a test that is used to establish or confirm the presence of a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(13)(a)">(a)</span> Specific disease; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(13)(b)">(b)</span> Hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(14)">(14)</span> “First screening” means a screening performed on the first blood-spot specimen collected from a newborn infant after birth.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(15)">(15)</span> “First–tier test” means a blood test performed on a newborn infant’s blood-spot specimen that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(15)(a)">(a)</span> Indicates the probable presence or absence of a hereditary or congenital disorder; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(15)(b)">(b)</span> Identifies a newborn infant who is at increased risk for a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(16)">(16)</span> “Follow-Up Unit” means the follow-up component and staff of the Department’s Newborn Screening Program, which carries out the duties set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12.12" title=".12 Follow-Up Procedures.">COMAR 10.52.12.12</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)">(17)</span> Hereditary Disorder.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(a)">(a)</span> "Hereditary disorder" means a disorder that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(a)(i)">(i)</span> Is transmissible through the genetic material deoxyribonucleic acid (DNA); or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(a)(ii)">(ii)</span> Arises through the improper processing of information in the genetic material.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(b)">(b)</span> "Hereditary disorder" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(b)(i)">(i)</span> Hemoglobin disorders;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(b)(ii)">(ii)</span> Metabolic disorders; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(b)(iii)">(iii)</span> Endocrine disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(18)">(18)</span> “Home birth” means the birth of an infant which occurs intentionally outside of a birthing facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(19)">(19)</span> “Home birth attendant” means a physician who is licensed to practice under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 14, Annotated Code of Maryland</a>, a nurse midwife who is licensed and certified under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 8, Annotated Code of Maryland</a>, or a direct-entry midwife who is licensed under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 8, Subtitle 6C, Annotated Code of Maryland</a>, who is caring for the mother and infant at delivery during a home birth as defined in <a class="internal-link " href="/us/md/exec/comar/10.10.13.03#B(18)" title="">§B(18) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(20)">(20)</span> "Metabolic Disorder" means a disorder caused by a genetic alteration that results in a defect in the function of a specific enzyme, hormone, or protein, which can be detected by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(20)(a)">(a)</span> Direct analysis of the enzyme, hormone, or protein; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(20)(b)">(b)</span> Testing for a substance whose metabolism is altered as a result of the defect.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)">(21)</span> "Newborn" or "newborn infant" means an infant:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(a)">(a)</span> Born in Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(b)">(b)</span> Born on federal property within Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(c)">(c)</span> Born outside of Maryland to parents whose residence is in Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(d)">(d)</span> From whom a blood-spot specimen was collected and submitted to the Department’s public health laboratory for newborn screening by a birthing facility or other health care provider located in Maryland, regardless of the infant’s place of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(e)">(e)</span> Who has a screening test requested by the Follow-Up Unit:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(e)(i)">(i)</span> For first-tier screening follow-up;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(e)(ii)">(ii)</span> For confirmation of a previous screening test result; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(e)(iii)">(iii)</span> To assist with a newborn infant's diagnosis, therapy, or follow-up care; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(f)">(f)</span> Who is in Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)">(22)</span> Newborn Screening or Screening.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)(a)">(a)</span> "Newborn screening" or "screening" means one or more first-tier tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)(b)">(b)</span> "Newborn screening" or "screening" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)(b)(i)">(i)</span> First-tier testing on a first, second, or subsequent blood-spot specimen; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)(b)(ii)">(ii)</span> Supplemental first-tier testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)">(23)</span> Newborn Screening Program.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)">(a)</span> "Newborn Screening Program" means the Department's screening program for hereditary and congenital disorders, which performs operations and activities necessary to ensure that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(i)">(i)</span> Newborn infants are given the opportunity to be tested;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(ii)">(ii)</span> At risk newborn infants who are tested are identified and located;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(iii)">(iii)</span> Newborn infants are given access to necessary follow-up testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(iv)">(iv)</span> Diagnostic tests are available and the diagnosis is made or ruled out; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(v)">(v)</span> Newborn infants diagnosed with a hereditary or congenital disorder are given access to treatment.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)">(b)</span> "Newborn Screening Program" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(i)">(i)</span> The Department's public health laboratory as the sole screening laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(ii)">(ii)</span> Another state's public health laboratory or a commercial laboratory that may serve the State as a screening laboratory during an emergency under a Departmental mutual aid agreement;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(iii)">(iii)</span> Supplemental and second-tier testing performed by a state public health laboratory or by a permitted commercial or research laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(iv)">(iv)</span> The Follow-Up Unit; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(v)">(v)</span> The State Advisory Council on Hereditary and Congenital Disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(24)">(24)</span> "Normal limit" means a measurable, numerical value or range that is considered not to indicate or establish the presence of a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(25)">(25)</span> "Permittee" means a person issued a permit by the Secretary to operate a medical laboratory as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(26)">(26)</span> "Public health laboratory" means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(26)(a)">(a)</span> The Department's public health laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(26)(b)">(b)</span> Another state's public health laboratory or a commercial laboratory permitted in Maryland that is approved under a Departmental emergency mutual aid agreement to perform newborn screening tests on Maryland newborns.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)">(27)</span> Quality Assessment Plan.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)">(a)</span> "Quality assessment plan" means a planned system of step-by-step activities to ensure that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)(i)">(i)</span> Testing is carried out according to the manufacturer's instructions;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)(ii)">(ii)</span> Testing results are accurate and reliable;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)(iii)">(iii)</span> Testing problems and errors are found and corrected to avoid adverse health outcomes for newborn infants; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)(iv)">(iv)</span> Testing results are reported and communicated in a timely manner as required by this chapter.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(b)">(b)</span> "Quality assessment plan" includes the ongoing activities that monitor, review, evaluate, and improve the overall quality of the procedures and processes before, during, and after a test is performed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(28)">(28)</span> "Quality control" has the meaning stated in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.03#B" title="">COMAR 10.10.06.03B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)">(29)</span> Screening Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(a)">(a)</span> "Screening test" means a first-tier test used to detect a hereditary or congenital disorder listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12" title=".12 First-Tier, Supplemental, and Second-Tier Tests.">Regulation .12 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(b)">(b)</span> “Screening test” includes a test performed on a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(b)(i)">(i)</span> First screening blood-spot specimen;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(b)(ii)">(ii)</span> Second screening blood-spot specimen; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(b)(iii)">(iii)</span> Subsequent screening blood-spot specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(c)">(c)</span> "Screening test" does not include a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(c)(i)">(i)</span> Diagnostic test; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(c)(ii)">(ii)</span> Second-tier test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(30)">(30)</span> “Second screening” means a test performed on a routine second blood-spot specimen collected when the newborn infant is between 10 and 14 days old even though the test results from the newborn’s first blood-spot specimen were normal.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)">(31)</span> Second-Tier Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(a)">(a)</span> “Second-tier test” means a test performed on a newborn screening blood-spot specimen when a first-tier test provides an abnormal screening test result or a borderline abnormal screening test result.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(b)">(b)</span> "Second-tier test" includes a test that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(b)(i)">(i)</span> Establishes or confirms a newborn infant's risk for a hereditary or congenital disorder;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(b)(ii)">(ii)</span> Separates a newborn infant into a lower or higher risk category for a hereditary or congenital disorder; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(b)(iii)">(iii)</span> Is diagnostic because it confirms the presence of a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(32)">(32)</span> "Secretary" means the Secretary of Health or the Secretary's designee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(33)">(33)</span> “Supplemental test” means a test performed on a blood-spot specimen collected from a newborn infant that is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(33)(a)">(a)</span> Used to detect a hereditary or congenital disorder not specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(33)(b)">(b)</span> Not required to be performed by the Department's public health laboratory under this chapter or <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(34)">(34)</span> “Unsatisfactory blood-spot specimen” means a blood-spot specimen that may produce an inaccurate or unreliable test result because the blood-spot specimen exhibits one of the problems of collection as specified in Regulation .21B and C of this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.04" data-order="|10|10|13|.04|" data-ref-path="10|10|13|.04" class="h__section">.04 Permit.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A">A.</span> Eligibility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(1)">(1)</span> Except as set forth in a Departmental mutual aid agreement, the Department's public health laboratory is the sole laboratory that may hold a State permit to perform and that may perform a first-tier newborn screening test on a newborn infant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(2)">(2)</span> A medical laboratory other than the State's public health laboratory may obtain a permit to perform:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(2)(a)">(a)</span> A supplemental test;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(2)(b)">(b)</span> A second-tier test; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(2)(c)">(c)</span> Supplemental and second-tier tests.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B">B.</span> Requirements. Before offering to perform or performing a first-tier, supplemental, or second-tier test on a blood-spot specimen collected from a newborn infant, a person shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(1)">(1)</span> Obtain and maintain a valid:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(1)(a)">(a)</span> Permit issued by the Secretary to operate a medical laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(1)(b)">(b)</span> CLIA Certificate from the U.S. Health and Human Services' Centers for Medicare and Medicaid Services; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(2)">(2)</span> Meet applicable standards and requirements for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(2)(a)">(a)</span> A medical laboratory, as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01" title="Chapter 01 General">COMAR 10.10.01</a>—.08; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(2)(b)">(b)</span> Testing for hereditary or congenital disorders in a newborn infant as set forth in this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.05" data-order="|10|10|13|.05|" data-ref-path="10|10|13|.05" class="h__section">.05 Inspection Requirements.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#A">A.</span> Inspection Authority. The Department may conduct on-site inspections of a permittee or applicant for a permit to perform supplemental or second-tier tests to screen for or diagnose congenital and hereditary disorders in newborn infants.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#B">B.</span> Inspection Types. The Department may conduct the following types of inspections to assess compliance with the requirements of this subtitle and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#B(1)">(1)</span> An initial inspection before issuing a permit;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#B(2)">(2)</span> A routine inspection during the permit period; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#B(3)">(3)</span> An inspection subsequent to a complaint.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.06" data-order="|10|10|13|.06|" data-ref-path="10|10|13|.06" class="h__section">.06 Fees.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#A">A.</span> Permit Fees. A permittee or applicant for a permit that is not exempt under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04.01#C" title="">COMAR 10.10.04.01C</a>, or that is not another state's public health laboratory approved to provide newborn screening tests under a Departmental mutual aid agreement, shall pay to the Department the applicable fees as required by <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04" title="Chapter 04 Medical Laboratories">COMAR 10.10.04</a> and this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#B">B.</span> Screening and Follow-up Fee Requirement. A birthing center or person responsible for having newborn screening carried out for a newborn infant born outside a birthing facility shall pay a fee of $163.74 per newborn infant to the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#C">C.</span> Screening and Follow-Up Fee Payment. A birthing center or person responsible for having newborn screening carried out for a newborn infant born outside a birthing facility shall pay to the Department the total fees owed:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#C(1)">(1)</span> On a quarterly basis; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#C(2)">(2)</span> Within 30 days of receiving an invoice from the Department.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.07" data-order="|10|10|13|.07|" data-ref-path="10|10|13|.07" class="h__section">.07 Director Requirement, Qualifications, and Responsibilities.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#A">A.</span> Director Requirement. A permittee that offers to perform or performs a first-tier, supplemental, or second-tier test shall employ a director.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B">B.</span> Director Qualifications. The director shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B(1)">(1)</span> Meet the qualifications for a medical laboratory director set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.04" title=".04 Permitted Laboratory Other than a POL or POCL — Director.">COMAR 10.10.07.04</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B(2)">(2)</span> Possess a current license as a laboratory director issued by the state in which the laboratory is located if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B(2)(a)">(a)</span> The laboratory is not located in Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B(2)(b)">(b)</span> Licensing is required by the state in which the laboratory is located.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C">C.</span> Director Responsibilities. The director is responsible for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(1)">(1)</span> The overall operation and administration of the laboratory, including the employment of a sufficient number of competent personnel;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(2)">(2)</span> Ensuring that each first-tier, supplemental, or second-tier test conducted is performed accurately and reliably in all aspects of the testing process, including the preanalytic, analytic, and post-analytic phases of the total testing process; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(3)">(3)</span> Ensuring compliance with:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(3)(a)">(a)</span> This chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(3)(b)">(b)</span> The applicable parts of <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01" title="Chapter 01 General">COMAR 10.10.01</a>— <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08" title="Chapter 08 Medical Laboratories — Sanctions">10.10.08</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(3)(c)">(c)</span> <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.08" data-order="|10|10|13|.08|" data-ref-path="10|10|13|.08" class="h__section">.08 Technical Supervisor Requirement, Qualifications, and Responsibilities.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#A">A.</span> Technical Supervisor Requirement. A permittee that offers to perform or performs a first-tier, supplemental, or second-tier test shall employ a technical supervisor.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#B">B.</span> Director as Technical Supervisor. The director may function as the technical supervisor if the director meets the technical supervisor qualifications specified in this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#C">C.</span> Technical Supervisor Qualifications. The technical supervisor shall meet the qualifications for a technical supervisor set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.05#A(1)" title="">COMAR 10.10.07.05A(1)</a> and B(7).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D">D.</span> Technical Supervisor Responsibilities. A technical supervisor shall be:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(1)">(1)</span> Responsible for the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(1)(a)">(a)</span> Technical and scientific methods used in the laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(1)(b)">(b)</span> Oversight of the laboratory;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(2)">(2)</span> Available to the laboratory personnel on an as-needed basis to provide supervision as specified in this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(3)">(3)</span> Accessible to the laboratory to provide on-site, telephonic, or electronic consultation to laboratory personnel and clients.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.09" data-order="|10|10|13|.09|" data-ref-path="10|10|13|.09" class="h__section">.09 Clinical Consultant Requirement, Qualifications, and Responsibilities.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#A">A.</span> Clinical Consultant Requirement. A permittee that offers to perform or performs first-tier, supplemental, or second-tier tests shall employ a clinical consultant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#B">B.</span> Director as Clinical Consultant. The director may function as the clinical consultant if the director meets the qualifications set forth under <a class="internal-link " href="/us/md/exec/comar/10.10.13.09#C" title="">§C of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C">C.</span> Clinical Consultant Qualifications. The clinical consultant shall be:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(1)">(1)</span> A doctor of medicine or a doctor of osteopathy licensed to practice medicine or osteopathy; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(2)">(2)</span> Board certified by the American Board of Medical Genetics as a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(2)(a)">(a)</span> Clinical geneticist;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(2)(b)">(b)</span> Medical geneticist; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(2)(c)">(c)</span> Biochemical geneticist.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D">D.</span> Clinical Consultant Responsibilities. A clinical consultant shall provide clinical consultation related to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D(1)">(1)</span> Inquiries concerning specific newborn screening tests;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D(2)">(2)</span> Interpretation of specific test results;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D(3)">(3)</span> Possible diagnostic or supplemental testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D(4)">(4)</span> Assistance in ensuring that appropriate tests are ordered to meet clinical expectations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.10" data-order="|10|10|13|.10|" data-ref-path="10|10|13|.10" class="h__section">.10 General Supervisor Requirement, Qualifications, and Responsibilities.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#A">A.</span> General Supervisor Requirement. A permittee that offers to perform or performs first-tier, supplemental, or second-tier tests shall employ a general supervisor.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B">B.</span> General Supervisor Qualifications. The general supervisor shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(1)">(1)</span> Meet the qualifications for a general supervisor set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.06#B(1)" title="">COMAR 10.10.07.06B(1)</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)">(2)</span> Have at least 6 months experience supervising the operation of applicable test systems, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)(a)">(a)</span> Tandem mass spectrophotometry (MS/MS);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)(b)">(b)</span> Time-resolved immunofluorometry;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)(c)">(c)</span> Enzyme-linked immunosorbent assay (ELISA) systems; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)(d)">(d)</span> Isoelectric focusing and high-performance liquid chromatography.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C">C.</span> General Supervisor Responsibilities. A general supervisor shall carry out the responsibilities set forth in 42 CFR §493.1463, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C(1)">(1)</span> Supervising the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C(1)(a)">(a)</span> Day-to-day operation of the laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C(1)(b)">(b)</span> Personnel performing tests and reporting test results; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C(2)">(2)</span> Being accessible to testing personnel at all times testing is performed to provide on-site, telephonic, or electronic consultation and resolve technical problems in accordance with policies and procedures established and approved by the director and technical supervisor.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.11" data-order="|10|10|13|.11|" data-ref-path="10|10|13|.11" class="h__section">.11 Testing Personnel Requirement and Qualifications.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.11#A">A.</span> Requirement. A permittee that offers to perform or performs first-tier, supplemental, or second-tier tests shall employ sufficient laboratory testing personnel to perform testing in accordance with the requirements of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.11#B">B.</span> Qualifications. Testing personnel shall meet the qualifications set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.07" title=".07 Permitted Laboratory Other than POL or POCL — Testing Personnel.">COMAR 10.10.07.07</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.12" data-order="|10|10|13|.12|" data-ref-path="10|10|13|.12" class="h__section">.12 First-Tier, Supplemental, and Second-Tier Tests.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#A">A.</span> First-Tier Tests; Requirement. The Department’s public health laboratory shall perform first-tier tests on all screening blood-spot specimens collected from a newborn infant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#B">B.</span> First-Tier Tests; Testing Limitations.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#B(1)">(1)</span> Only the Department's public health laboratory may screen for the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">§C of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#B(2)">(2)</span> A permittee may perform a supplemental or a second-tier test only when the test is requested by an individual authorized to request a medical laboratory test as provided in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.02" title=".02 Authorization to Request Laboratory Tests.">COMAR 10.10.06.02</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C">C.</span> First-Tier Tests. The Department’s public health laboratory shall perform a first-tier test on a newborn infant to screen for the following hereditary and congenital disorders, which are approved for screening by the Council and the Secretary:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(1)">(1)</span> Biotinidase deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(2)">(2)</span> Congenital adrenal hyperplasia (CAH);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(3)">(3)</span> Hypothyroidism;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(4)">(4)</span> Galactosemia, galactose-1-phosphate uridyl transferase deficiency (GALT);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(5)">(5)</span> Epimerase Galactosemia, uridine diphosphate-galactose-4-epimerase deficiency (GALE);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(6)">(6)</span> Galactokinase Galactosemia, galactokinase deficiency (GALK1);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(7)">(7)</span> Sickle cell disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(8)">(8)</span> Sickle cell disease: S beta-thalessemia;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(9)">(9)</span> Sickle C disease: SC disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(10)">(10)</span> Other hemoglobin variants;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(11)">(11)</span> Phenylketonuria (PKU);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(12)">(12)</span> Hyperphenylalaninemia (Hyper-PHE);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(13)">(13)</span> Biopterin cofactor biosynthesis defects (BIOPT-BS);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(14)">(14)</span> Biopterin cofactor regeneration defects (BIOPT-REG);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(15)">(15)</span> Tyrosinemia, type I;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(16)">(16)</span> Tyrosinemia, type II;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(17)">(17)</span> Tyrosinemia, type III;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(18)">(18)</span> Homocystinuria;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(19)">(19)</span> Hypermethioninemia;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(20)">(20)</span> Branched chain ketoaciduria (BCK), also called maple syrup urine disease (MSUD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(21)">(21)</span> Citrullinemia, type I;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(22)">(22)</span> Citrullinemia, type II;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(23)">(23)</span> Arginosuccinic aciduria;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(24)">(24)</span> Argininemia;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(25)">(25)</span> Methylmalonic acidemia, mutase deficiency (MMA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(26)">(26)</span> Methylmalonic acidemia, adenosylcobalamin synthesis defects A and B (Cbl A, B);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(27)">(27)</span> Methylmalonic acidemia, adenosylcobalamin synthesis defects C and D (Cbl C, D);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(28)">(28)</span> Propionic acidemia (PA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(29)">(29)</span> Isovaleric acidemia (IVA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(30)">(30)</span> Glutaric aciduria type I (GA I);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(31)">(31)</span> 3-Hydroxy-3-methylglutaryl-CoA (HMG) lysase deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(32)">(32)</span> Isobutryl-CoA dehydrogenase (IBCD) deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(33)">(33)</span> 2-Methylbutyryl-CoA dehydrogenase deficiency (2MBG);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(34)">(34)</span> 3-Methlycrotonyl-CoA carboxylase deficiency (3MCC);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(35)">(35)</span> 3-Methlyglutaconyl-CoA hydratase deficiency (3MGA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(36)">(36)</span> 2-Methyl-3-hydroxybutyrl-CoA dehydrogenase deficiency (2M3HBA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(37)">(37)</span> Mitochondrial acetoacetyl-CoA thiolase (3-ketothiolase) deficiency (BKT);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(38)">(38)</span> Multiple carboxylase deficiency (MCD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(39)">(39)</span> Malonic acidemia (MAL);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(40)">(40)</span> Medium chain acyl-CoA dehydrogenase deficiency (MCAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(41)">(41)</span> Medium chain ketoacyl-CoA thiolase deficiency (MCKAT);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(42)">(42)</span> Short chain acyl-CoA dehydrogenase deficiency (SCAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(43)">(43)</span> Short chain 3-hydroxy acyl Co-A dehydrogenase deficiency (SCHAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(44)">(44)</span> Very long chain acyl-CoA dehydrogenase deficiency (VLCAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(45)">(45)</span> 3-hydroxy long chain acyl-CoA dehydrogenase deficiency (LCHAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(46)">(46)</span> Multiple acyl-CoA dehydrogenase (MAD) or glutaric acidemia type II deficiency (GA II);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(47)">(47)</span> Carnitine/acylcarnitine translocase deficiency (translocase deficiency);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(48)">(48)</span> Carnitine palmitoyl transferase type I deficiency (CPT I);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(49)">(49)</span> Carnitine palmitoyl transferase type II deficiency (CPT II);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(50)">(50)</span> Carnitine uptake disorder;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(51)">(51)</span> Trifunctional protein deficiency (TFP);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(52)">(52)</span> 2,4-dienoyl-CoA reductase deficiency (DE RED);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(53)">(53)</span> Cystic fibrosis;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(54)">(54)</span> Severe combined immunodeficiency (SCID);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(55)">(55)</span> Pompe disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(56)">(56)</span> Fabry disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(57)">(57)</span> Spinal muscular atrophy (SMA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(58)">(58)</span> Mucopolysaccharidosis type I (MPS I);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(59)">(59)</span> Mucopolysaccharidosis type II (MPS II);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(60)">(60)</span> X-linked Adrenoleukodystrophy (X-ALD); and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(61)">(61)</span> Guanidinoacetate Methyltransferase Deficiency (GAMT).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D">D.</span> Approved Methods:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)">(1)</span> A permittee shall use:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(a)">(a)</span> A colorimetric method for testing for a biotinidase deficiency, which is the disorder listed at <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(1)" title="">§C(1) of this regulation</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(b)">(b)</span> A fluorometric method when testing for galactosemia, which is the disorder listed at §C(4)—(6) of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(c)">(c)</span> A fluorescent-linked immunoassay method when testing for the hereditary or congenital disorders listed in §C(2) and (3) of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(d)">(d)</span> Isoelectric focusing followed by high-performance liquid chromatography when testing for sickle cell disease, which is the disorder listed at §C(7)—(10) of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(e)">(e)</span> Tandem mass-spectrometry when testing for the metabolic disorders listed in §C(11)—(52) of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(f)">(f)</span> IRT/IRT (immunoreactive trypsinogen/immuno-reactive trypsinogen) when testing for cystic fibrosis, which is the disorder listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(53)" title="">§C(53) of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(g)">(g)</span> Real time polymerase chain reaction method when testing for severe combined immunodeficiency, which is listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(54)" title="">§C(54) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(2)">(2)</span> A permittee shall have 60 days from the amendment's effective date to comply with any amendment made by the Secretary to <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#D" title="">§D of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.13" data-order="|10|10|13|.13|" data-ref-path="10|10|13|.13" class="h__section">.13 Screening Test Blood-Spot Specimens — Collection and Test Requisition.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A">A.</span> Blood-Spot Specimen Collection.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(1)">(1)</span> A person shall collect a newborn infant’s blood-spot specimen for testing under this chapter by using only the special blood-spot specimen collection test requisition card provided by the Department.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(2)">(2)</span> The Department shall provide the special blood-spot specimen collection test requisition card to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(2)(a)">(a)</span> Individual in charge of a birthing facility or the individual’s designated representative; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(2)(b)">(b)</span> Home birth attendant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(3)">(3)</span> The individual in charge of a birthing facility or the individual’s designated representative, or the home birth attendant shall collect a blood-spot specimen consisting of heel-stick whole blood obtained:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(3)(a)">(a)</span> When a newborn infant is 24 to 48 hours old;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(3)(b)">(b)</span> On a blood-spot specimen collection test requisition card provided by the Department; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(3)(c)">(c)</span> As set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.13.14" title=".14 Screening Test Blood-Spot Specimens — Procedures, Submission, and Delivery Requirements.">Regulation .14 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B">B.</span> Blood-Spot Specimen Collection Test Requisition Card Information. An individual shall record the following information as specified on the Department-supplied blood-spot specimen collection test requisition card:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)">(1)</span> Newborn infant information, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(a)">(a)</span> Name;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(b)">(b)</span> Date of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(c)">(c)</span> Time of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(d)">(d)</span> Current weight;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(e)">(e)</span> Gender;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(f)">(f)</span> Race;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(g)">(g)</span> Gestational age;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(h)">(h)</span> Birthing facility identification, including the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(h)(i)">(i)</span> Facility name;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(h)(ii)">(ii)</span> Facility street address, city, state, and zip code; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(h)(iii)">(iii)</span> Newborn infant's medical record or chart number;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(i)">(i)</span> Date and time of first feeding;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(j)">(j)</span> Type of feeding, such as:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(j)(i)">(i)</span> Breast;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(j)(ii)">(ii)</span> Lactose-containing formula; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(j)(iii)">(iii)</span> Formula containing no lactose;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(k)">(k)</span> Transfusion history, including transfusion date and time;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(l)">(l)</span> General health status of the newborn infant; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(m)">(m)</span> The total protein and calorie intake for any newborn infant in a neonatal intensive care setting;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(2)">(2)</span> Blood-spot specimen information, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(2)(a)">(a)</span> Date of collection;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(2)(b)">(b)</span> Time of collection; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(2)(c)">(c)</span> Initials or other identifier of the individual who collected the blood-spot specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(3)">(3)</span> Mother or guardian information, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(3)(a)">(a)</span> Name;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(3)(b)">(b)</span> Street address, city, state, and zip code; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(3)(c)">(c)</span> Telephone number where the mother or guardian may be reached;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(4)">(4)</span> Information on the pediatrician or attending physician who will be following the newborn infant, including the physician's:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(4)(a)">(a)</span> Name;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(4)(b)">(b)</span> Street address, city, state, and zip code; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(4)(c)">(c)</span> Telephone number; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(5)">(5)</span> Other information that can affect the test results or the interpretation of the test results when applicable, such as that antibiotics were administered to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(5)(a)">(a)</span> Mother; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(5)(b)">(b)</span> Newborn infant.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.14" data-order="|10|10|13|.14|" data-ref-path="10|10|13|.14" class="h__section">.14 Screening Test Blood-Spot Specimens — Procedures, Submission, and Delivery Requirements.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A">A.</span> Standard Operating Procedure. The individual in charge of a birthing facility or the individual’s designated representative, or the home birth attendant shall maintain written standard operating procedures for the collection, handling, storage, and transport of newborn infant blood-spot specimen collection test requisition cards, including instructions for staff to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(1)">(1)</span> Ensure and maintain blood-spot specimen integrity, quality, and acceptability;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(2)">(2)</span> Ensure proper:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(2)(a)">(a)</span> Site preparation and cleaning;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(2)(b)">(b)</span> Performance of the heel stick puncture; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(2)(c)">(c)</span> Application of whole blood to the collection test requisition card;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)">(3)</span> Identify precautions against:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(a)">(a)</span> Milking or squeezing the blood-spot specimen collection site;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(b)">(b)</span> Layering successive drops of blood on the same circle on the blood-spot specimen collection test requisition card;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(c)">(c)</span> Filling the circles on both sides of the filter paper;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(d)">(d)</span> Touching or smearing a blood-spot specimen before it is fully air-dried;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(e)">(e)</span> Scratching or abrading the blood-spot specimen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(f)">(f)</span> Not allowing a blood-spot specimen to dry thoroughly before sending the blood-spot specimen collection test requisition card to a laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(g)">(g)</span> Damaging, stretching, or wrinkling the filter paper before, during or after blood-spot specimen collection;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(4)">(4)</span> Recognize unsatisfactory blood-spot specimens; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(5)">(5)</span> Handle and temporarily store a blood-spot specimen collection test requisition card, including the procedures and techniques for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(5)(a)">(a)</span> Drying blood-spot specimens;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(5)(b)">(b)</span> Stacking of blood-spot specimen collection test requisition cards; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(5)(c)">(c)</span> Temporarily storing blood-spot specimen collection test requisition cards.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B">B.</span> Submission and Delivery Requirements. The individual in charge of a birthing facility or the individual’s designated representative, or the home birth attendant shall transport and deliver to the Department’s public health laboratory a newborn infant blood-spot specimen collection test requisition card using:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(1)">(1)</span> An employee or private courier;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(2)">(2)</span> A commercial carrier providing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(2)(a)">(a)</span> Overnight express delivery; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(2)(b)">(b)</span> Priority delivery;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(3)">(3)</span> A county or State operated courier system, where that service is available; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(4)">(4)</span> A combination of §B(1)—(3) of this regulation.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.15" data-order="|10|10|13|.15|" data-ref-path="10|10|13|.15" class="h__section">.15 Test Blood-Spot Specimens — Use, Research, Storage, and Retention.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#A">A.</span> Use. A permittee may use a newborn infant blood-spot specimen from a newborn infant to test for only the conditions listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B">B.</span> Research. A researcher may not use a Maryland newborn infant’s blood spot specimen or test results for research purposes unless the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B(1)">(1)</span> Research is approved in writing by the Department's:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B(1)(a)">(a)</span> Newborn Screening Program; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B(1)(b)">(b)</span> Institutional Review Board; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B(2)">(2)</span> Researcher acknowledges in writing that the researcher will return all untested blood-spot specimens to the Department’s public health laboratory within 6 months of completing the approved research.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#C">C.</span> Storage. A permittee or researcher shall store a newborn infant blood-spot specimen in a sealed, moisture-proof container at between 2ºC and 6ºC.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D">D.</span> Retention.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D(1)">(1)</span> A permittee shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D(1)(a)">(a)</span> Retain a newborn infant’s gel, produced when testing for hemoglobin disorders, for at least 90 days after testing is complete; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D(1)(b)">(b)</span> Return to the State’s public health laboratory all untested blood-spot specimens received from the Department’s public health laboratory for supplemental or diagnostic testing within 90 days after testing is completed by the permittee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D(2)">(2)</span> The Department’s public health laboratory shall retain and maintain for 25 years a newborn infant’s blood-spot specimen after the blood-spot specimen is received for screening, supplemental testing, or diagnostic testing.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.16" data-order="|10|10|13|.16|" data-ref-path="10|10|13|.16" class="h__section">.16 Test Records — Retention.</h2>
                <p>The Department’s public health laboratory shall retain and maintain electronically or as a hard copy for 25 years the:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#A">A.</span> Top copy of the requisition portion of the blood-spot specimen collection test requisition card;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#B">B.</span> All test results and reports;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#C">C.</span> Electronic data bases; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D">D.</span> Supporting documents that show how a reported test result was obtained and verified, including but not limited to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D(1)">(1)</span> Quality control records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D(2)">(2)</span> Instrument maintenance and repair records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D(3)">(3)</span> Test reagent records; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D(4)">(4)</span> Instrument and test system data.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.17" data-order="|10|10|13|.17|" data-ref-path="10|10|13|.17" class="h__section">.17 Testing — First-Tier.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#A">A.</span> The Department’s public health laboratory shall test, using first-tier tests, appropriately timed and collected blood-spot specimen of a newborn infant’s blood for the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B">B.</span> Full-Term Healthy Newborn Infants.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(1)">(1)</span> If a newborn infant is born at term and is healthy, the Department’s public health laboratory shall conduct a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(1)(a)">(a)</span> First screening using first-tier tests to detect the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a> on a blood-spot specimen collected when the full-term healthy newborn infant is between 24 and 48 hours old; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(1)(b)">(b)</span> Second screening using first-tier tests on a blood-spot specimen collected when the full-term healthy infant is between 10 and 14 days old.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(2)">(2)</span> If the first blood-spot specimen is collected when a full term healthy newborn infant is younger than 24 hours old, the Department’s public health laboratory shall conduct a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(2)(a)">(a)</span> Second screening using first-tier tests to detect the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a> on a blood-spot specimen collected when the newborn infant is between 24 hours and 7 days old; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(2)(b)">(b)</span> Third screening using first-tier tests on a blood-spot specimen collected when the full-term healthy infant is between 1 and 4 weeks old.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C">C.</span> Premature or Ill Newborn Infant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)">(1)</span> If a newborn infant who is born prematurely or expected to be ill for more than 14 days was younger than 24 hours old when the blood-spot specimen was collected for a first screening, the Department’s public health laboratory shall conduct a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(a)">(a)</span> Second screening using first-tier tests to detect the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a> when the newborn infant is between 24 hours and 3 days old; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)">(b)</span> Third screening using first-tier tests when the newborn infant is between 7 days and 14 days old to screen for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)(i)">(i)</span> Amino acid disorders as specified in Regulation .12C(11)—(24) of this chapter;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)(ii)">(ii)</span> Acylcarnitine disorders as specified in Regulation .12C(25)—(52) of this chapter;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)(iii)">(iii)</span> Congenital hypothyroidism as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(4)" title="">Regulation .12C(4) of this chapter</a>; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)(iv)">(iv)</span> Severe combined immunodeficiency, as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(54)" title="">Regulation .12C(54) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)">(2)</span> If a newborn infant who is born prematurely or expected to be ill for more than 14 days was 24 hours old or older at the time the newborn infant’s blood-spot specimen was collected for a first screening, the Department’s public health laboratory shall perform a second screening to screen for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)(a)">(a)</span> Amino acid disorders as specified in Regulation .12C(11)—(24) of this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)(b)">(b)</span> Acylcarnitine disorders as specified in Regulation .12C(25)—(52) of this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)(c)">(c)</span> Congenital hypothyroidism as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(4)" title="">Regulation .12C(4) of this chapter</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)(d)">(d)</span> Severe combined immunodeficiency, as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(54)" title="">Regulation .12C(54) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(3)">(3)</span> If a newborn infant was transfused before the blood-spot specimen was collected for a first screening, the Department’s public health laboratory shall conduct, in addition to any other screenings specified in §B(1) and (2) of this regulation, a fourth screening using first-tier tests on a blood-spot specimen collected 4 months after a newborn infant’s last transfusion to screen for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(3)(a)">(a)</span> Hemoglobin as specified in Regulation .12C(7)—(10) of this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(3)(b)">(b)</span> Biotinidase as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(1)" title="">Regulation .12C(1) of this chapter</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(3)(c)">(c)</span> Galactose-1-P-uridyl-1-transferase as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(3)" title="">Regulation .12C(3) of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.18" data-order="|10|10|13|.18|" data-ref-path="10|10|13|.18" class="h__section">.18 Testing — Second-Tier and Supplemental.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#A">A.</span> When a test request is made by an individual authorized to request a laboratory test, as set out in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.02" title=".02 Authorization to Request Laboratory Tests.">COMAR 10.10.06.02</a>:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#A(1)">(1)</span> A permittee other than the Department's public health laboratory may perform a second-tier or supplemental test; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#A(2)">(2)</span> The Department's public health laboratory may perform a second-tier test.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#B">B.</span> A permittee:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#B(1)">(1)</span> May not contract out, subcontract, or otherwise transfer supplemental or second-tier testing to another laboratory that does not hold a Maryland permit in the discipline of diagnostic and supplemental testing for hereditary and congenital disorders in newborns;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#B(2)">(2)</span> Shall complete a second-tier or supplemental test on a blood-spot specimen within 3 working days after the blood-spot specimen arrives at the laboratory; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#B(3)">(3)</span> Shall report the results of a second-tier or supplemental screening test as required in Regulations .23 and .24 of this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.19" data-order="|10|10|13|.19|" data-ref-path="10|10|13|.19" class="h__section">.19 Proficiency and Competency Testing for Newborn Screening Tests.</h2>
                <p>A permittee shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.19#A">A.</span> Meet all requirements set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05" title="Chapter 05 Medical Laboratories — Proficiency Testing">COMAR 10.10.05</a>;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.19#B">B.</span> Successfully participate in one or more approved proficiency testing programs that cover all first-tier, second-tier, and supplementary tests offered or performed;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.19#C">C.</span> Evaluate and document performance, semiannually during the first year of testing and annually thereafter, of all individuals responsible for testing; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.19#D">D.</span> In addition to the proficiency testing requirement in <a class="internal-link " href="/us/md/exec/comar/10.10.13.19#A" title="">§A of this regulation</a>, participate in the Centers for Disease Control and Prevention's Newborn Screening Quality Assurance Program.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.20" data-order="|10|10|13|.20|" data-ref-path="10|10|13|.20" class="h__section">.20 Quality Control.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A">A.</span> Quality Control Program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(1)">(1)</span> A permittee shall develop, establish, implement, maintain and follow written quality control policies, procedures, and techniques that provide and ensure accurate, reliable, and valid test results and reports.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(2)">(2)</span> A permittee's quality control program shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(2)(a)">(a)</span> Cover all tests, methods, and procedures performed by the laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(2)(b)">(b)</span> Meet the standards and requirements set forth in this chapter and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06" title="Chapter 06 Medical Laboratories — Quality Assurance">COMAR 10.10.06</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)">(3)</span> A permittee's quality control procedures and practices shall include, but are not limited to, the use of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(a)">(a)</span> Analyses of reference materials to ensure the reproducibility and accuracy of test results;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(b)">(b)</span> Systems to ensure proper functioning of instruments, equipment, reagents, and performance of laboratory personnel;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(c)">(c)</span> Valid reagents, equipment, calibration, and systematic procedural checks;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(d)">(d)</span> A system that ensures timely and pertinent error detection and correction for the review and reporting of test results; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(e)">(e)</span> Quality control materials from the Centers for Disease Control and Prevention's Newborn Screening Quality Assurance Program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B">B.</span> Adequacy of Methods and Equipment. To ensure the adequacy of test methods, test systems, and equipment, a permittee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(1)">(1)</span> Employ methods, test systems, and equipment that provide accurate and reliable test results and reports;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(2)">(2)</span> Have sufficient and suitable equipment and instruments to perform the type and volume of tests offered and performed by the laboratory;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(3)">(3)</span> Perform tests in a manner that provides accurate and reliable test results;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)">(4)</span> Monitor test methods, instruments, and testing systems, where applicable, for the following performance characteristics:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(a)">(a)</span> Method, instrument, and test system detection limits and cutoff levels;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(b)">(b)</span> Precision;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(c)">(c)</span> Accuracy;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(d)">(d)</span> Specificity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(e)">(e)</span> Sensitivity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(f)">(f)</span> Interferences; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(g)">(g)</span> Other related test variables that affect test results; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)">(5)</span> Have adequate quality control systems and procedures in place to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(a)">(a)</span> Obtain and verify a statistically valid number of counts or measurement levels to give accurate and reliable test results for an analytical instrument, each day an instrument is used for testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(b)">(b)</span> Report results:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(b)(i)">(i)</span> As set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.04" title=".04 Reporting and Releasing Test Results.">COMAR 10.10.06.04</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(b)(ii)">(ii)</span> As set forth in 42 CFR §493.1291; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(b)(iii)">(iii)</span> Within the time frames required by this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C">C.</span> Supplies, Reagents, and Materials.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(1)">(1)</span> A permittee shall ensure that supplies, reagents, and other materials used in the collected, handling, testing, and storing of newborn blood-spot specimens are stored, labeled, checked for proper reactivity, and used according to the provisions of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)">(2)</span> A permittee shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)">(a)</span> Label laboratory supplies and materials used in the testing process, including reagents, solutions, controls, and calibrators to indicate the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(i)">(i)</span> Identity of reagents, solutions, controls, and calibrators;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(ii)">(ii)</span> Strength or concentration;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(iii)">(iii)</span> Storage requirements;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(iv)">(iv)</span> Preparation and expiration date;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(v)">(v)</span> Identity of the preparer; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(vi)">(vi)</span> Other pertinent information that affects test performance;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(b)">(b)</span> Store laboratory materials in the manner recommended by the manufacturer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(c)">(c)</span> Test representative samples of each lot of materials used for or in the process of testing blood-spot specimens on a regularly scheduled basis to determine that each lot of test material is capable of performing as required; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(d)">(d)</span> Use supplies, reagents, kits, test systems, and other materials in a manner consistent with the recommendations and instructions provided by the manufacturer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(3)">(3)</span> A permittee may not use supplies, reagents, kits, test systems, or other materials in the testing process that have:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(3)(a)">(a)</span> Exceeded the materials' established expiration dates;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(3)(b)">(b)</span> Substandard reactivity; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(3)(c)">(c)</span> Deteriorated.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.21" data-order="|10|10|13|.21|" data-ref-path="10|10|13|.21" class="h__section">.21 Quality Assessment and Quality Assurance.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A">A.</span> A permittee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(1)">(1)</span> Establish and follow a written quality assessment plan that covers all phases of the testing process;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(2)">(2)</span> Meet the applicable quality assurance requirements of <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06" title="Chapter 06 Medical Laboratories — Quality Assurance">COMAR 10.10.06</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(3)">(3)</span> Have an accessioning mechanism or system that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(3)(a)">(a)</span> Tracks blood-spot specimens and allows first and subsequent blood-spot specimens and test results from the same newborn infant to be linked for testing and analysis; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(3)(b)">(b)</span> Identifies a specific analyte that requires retesting when a newborn infant's prior screening test results for that analyte are abnormal or border-line abnormal.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B">B.</span> A permittee may not test a blood-spot specimen exhibiting:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(1)">(1)</span> Blood that did not saturate the filter paper;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(2)">(2)</span> A circle containing no blood;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(3)">(3)</span> A blood clot or tissue on the surface of the blood;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(4)">(4)</span> A circle over-saturated with blood showing dark areas in the circle or at the perimeter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(5)">(5)</span> Blood that appears layered or clotted; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(6)">(6)</span> Serum rings or blood that appears diluted, discolored, or contaminated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C">C.</span> A permittee may not test a blood-spot specimen:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(1)">(1)</span> Collected more than 10 days before the screening test is to be started;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)">(2)</span> That is unaccompanied by information necessary for the testing to be meaningful, including the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(a)">(a)</span> Age of the newborn infant;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(b)">(b)</span> Identification of the newborn infant;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(c)">(c)</span> Date and time of blood-spot specimen collection;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(d)">(d)</span> Date and time of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(e)">(e)</span> Newborn infant's weight; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(f)">(f)</span> Date and time of a newborn infant's first feeding;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(3)">(3)</span> If an infant was transfused before the first screening and the repeat blood-spot specimen collected to test for hemoglobin was drawn earlier than 4 months after the last transfusion; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(4)">(4)</span> If the newborn infant was younger than 24 hours old or the newborn's age was unknown at the time of collection and the requested screening test is for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(4)(a)">(a)</span> Congenital adrenal hyperplasia as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(2)" title="">Regulation .12C(2) of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(4)(b)">(b)</span> Thyroxine or thyroid stimulating hormone as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(4)" title="">Regulation .12C(4) of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#D">D.</span> Within 24 hours of receipt of an unsatisfactory blood-spot specimen, the permittee shall notify the submitter of the unsatisfactory blood-spot specimen by telephone, facsimile, or electronic mail:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#D(1)">(1)</span> That the blood-spot specimen cannot be tested; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#D(2)">(2)</span> To submit another blood-spot specimen as soon as possible.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E">E.</span> If a permittee reports a test result on a newborn infant and later discovers that the test result was erroneous or questionable, the permittee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(1)">(1)</span> Give prompt notice of the erroneous or questionable patient test result to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(1)(a)">(a)</span> Person who requested that the test be performed;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(1)(b)">(b)</span> Physician or other person to whom the laboratory has previously sent a report that contained the erroneous or questionable result; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(1)(c)">(c)</span> Follow-Up Unit;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(2)">(2)</span> Provide corrected reports to the persons notified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.21#E" title="">§E of this regulation</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(3)">(3)</span> Maintain duplicates of both the original report and the corrected report;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(4)">(4)</span> Conduct a quality assessment of all phases of the testing process to determine the cause of the erroneous or questionable test result;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(5)">(5)</span> Take the necessary remedial or corrective action to prevent recurrence of the problem; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)">(6)</span> Take any additional measures necessary to reduce or eliminate the threat to the health and safety of the patient including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)(a)">(a)</span> Notifying a parent or guardian of the newborn infant of the erroneous or questionable result;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)(b)">(b)</span> Retesting the same blood-spot specimen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)(c)">(c)</span> Testing a new blood-spot specimen; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)(d)">(d)</span> Retesting the same blood-spot specimen and testing a new blood-spot specimen.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.22" data-order="|10|10|13|.22|" data-ref-path="10|10|13|.22" class="h__section">.22 Quality Assurance — Continuity of Operations and Disaster Recovery Plan.</h2>
                <p>A permittee shall develop, implement, and maintain written continuity of operations and disaster recovery plans that ensure the continuous performance of essential functions and operations:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.22#A">A.</span> During an emergency; or</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.22#B">B.</span> When the laboratory temporarily can no longer meet the requirements and standards set forth in this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.23" data-order="|10|10|13|.23|" data-ref-path="10|10|13|.23" class="h__section">.23 Reporting Test Results.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A">A.</span> All Test Results. For a newborn infant, a permittee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)">(1)</span> Report all first-tier, supplemental, and second-tier results to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)(a)">(a)</span> The person who requested the test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)(b)">(b)</span> An individual who will use the test results in identifying, tracking, caring for, and treating the newborn infant, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)(b)(i)">(i)</span> A physician specialist; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)(b)(ii)">(ii)</span> Personnel in the Follow-Up Unit;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(2)">(2)</span> Report to the persons listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.23#A(1)" title="">§A(1) of this regulation</a> within 3 working days after the laboratory obtains the blood-spot specimen, all test results that are within normal limits;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(3)">(3)</span> Report to a person requesting a second or subsequent screening the test results from the newborn infant's prior screening if not previously reported to the person;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(4)">(4)</span> Include with each report the following information:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(4)(a)">(a)</span> Date the blood-spot specimen was received in the laboratory;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(4)(b)">(b)</span> Date of the report; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(4)(c)">(c)</span> Cut-off level for each reported analyte; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(5)">(5)</span> Report all abnormal test results to the Follow-Up Unit on the same day that a test result is obtained and reviewed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B">B.</span> Specific Test results. A permittee may not report a test result as being within normal limits for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(1)">(1)</span> Amino acid levels for disorders specified in Regulation .12C(11)—(24) of this chapter and for a total galactose level for galactosemia as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(3)" title="">Regulation .12C(3) of this chapter</a> if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(1)(a)">(a)</span> A newborn infant was not on milk or formula feeding at least 24 hours before the blood-spot specimen was collected; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(1)(b)">(b)</span> The time of milk or formula feeding is unknown; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(2)">(2)</span> 17-hydroxy progesterone results for congenital adrenal hyperplasia as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(2)" title="">Regulation .12C(2) of this chapter</a> and thyroxine and thyroid stimulating hormone for hypothyroidism as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(4)" title="">Regulation .12C(4) of this chapter</a> if the blood-spot specimen was collected when the newborn infant was:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(2)(a)">(a)</span> Younger than 24 hours old; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(2)(b)">(b)</span> Of unknown age.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.24" data-order="|10|10|13|.24|" data-ref-path="10|10|13|.24" class="h__section">.24 Reporting Abnormal Test Results to the Follow-Up Unit.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#A">A.</span> Reporting Requirements. A permittee shall immediately report an abnormal or diagnostic test result to the Follow-Up Unit by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#A(1)">(1)</span> Telephoning and personally speaking to an individual in the Follow-Up Unit;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#A(2)">(2)</span> Telephoning and personally speaking to a back-up individual representing the Follow-Up Unit, if an attempt to make in-person contact with an employee of the Follow-Up Unit fails; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#A(3)">(3)</span> Following up a telephonic report within 24 hours with a report by facsimile or electronic mail to the Follow-Up Unit.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#B">B.</span> Verification Requirement. A permittee shall contact the Follow-Up Unit by telephone at least once every 6 months to ensure that the permittee is able to meet the requirements in <a class="internal-link " href="/us/md/exec/comar/10.10.13.24#A" title="">§A of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C">C.</span> Reporting Requirements; General. A permittee shall provide with each abnormal result, where applicable, the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(1)">(1)</span> Identity or name of each analyte measured;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(2)">(2)</span> Measured numerical concentration or range of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(2)(a)">(a)</span> Each analyte measured; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(2)(b)">(b)</span> All related analytes measured;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(3)">(3)</span> Value of any relevant ratios used to determine abnormality;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(4)">(4)</span> Postnatal age of the newborn infant;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(5)">(5)</span> Appropriate gestational age/birth weight control range;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(6)">(6)</span> Cut-off level for the analyte of a hereditary or congenital disorder; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(7)">(7)</span> Measure of the degree of abnormality of the test result.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D">D.</span> Reporting Requirements; Sickle Cell Disease Hemoglobin. A permittee shall report results for hemoglobin disorders as specified in Regulation .12C(7)—(10) of this chapter for sickle cell disease in terminology that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(1)">(1)</span> The alleles present in decreasing quantitative order; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)">(2)</span> Specifying trait states and possible disease states for at least the following alleles:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(a)">(a)</span> Hemoglobin C;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(b)">(b)</span> Hemoglobin D;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(c)">(c)</span> Hemoglobin E;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(d)">(d)</span> Hemoglobin G;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(e)">(e)</span> Hemoglobin O; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(f)">(f)</span> Hemoglobin S.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.25" data-order="|10|10|13|.25|" data-ref-path="10|10|13|.25" class="h__section">.25 Reporting System and Communication Software.</h2>
                <p>A permittee shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#A">A.</span> Have available and use a reliable and accurate electronic information system that is capable of collecting, compiling, transferring, and communicating all normal and abnormal test results to the Follow-Up Unit; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B">B.</span> Provide the Follow-Up Unit, where applicable, with:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B(1)">(1)</span> The necessary information system and electronic communications software or interface to be used by the Follow-Up Unit to receive from the permittee the newborn screening test results and reports required in this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B(2)">(2)</span> Software programming assistance to ensure that the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B(2)(a)">(a)</span> Permittee's data transmitted to the Follow-Up Unit is accurate and timely; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B(2)(b)">(b)</span> The Follow-Up Unit's information system maintains compatibility with the permittee's information system.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.26" data-order="|10|10|13|.26|" data-ref-path="10|10|13|.26" class="h__section">.26 Availability of Statistical and Scientific Data.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#A">A.</span> Statistical Reports. The State’s public health laboratory, the Follow-Up Unit, or both, on request, shall provide Newborn Screening Program statistical data for official State and national reports to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#A(1)">(1)</span> The Council;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#A(2)">(2)</span> The Department's Office of Genetics and Children with Special Healthcare Needs; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#A(3)">(3)</span> State and federal agencies that use test results and statistics for the care and treatment of newborn infants.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#B">B.</span> Research Investigations. The Laboratories Administration, the Follow-Up Unit, or both, may participate in research investigations approved by the Department's Institutional Review Board.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13.27" data-order="|10|10|13|.27|" data-ref-path="10|10|13|.27" class="h__section">.27 Sanctions.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A">A.</span> Due to the life-threatening nature and effect of errors in newborn screening testing, the Secretary may order summarily the suspension of a permit if the Secretary finds that the public health, safety, or welfare imperatively requires emergency action, including but not limited to, if a permittee has:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(1)">(1)</span> Failed to report a newborn infant's abnormal test result as required in this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(2)">(2)</span> Falsified a document submitted to the Department, including but not limited to a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(2)(a)">(a)</span> Newborn infant screening test report; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(2)(b)">(b)</span> Quality control or quality assurance report; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(3)">(3)</span> Failed to provide a corrected or amended test report if the permittee has reported an erroneous or questionable test result.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#B">B.</span> If the Secretary summarily suspends a permit as provided in <a class="internal-link " href="/us/md/exec/comar/10.10.13.27#A" title="">§A of this regulation</a>, the Secretary shall promptly give the permittee:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#B(1)">(1)</span> Written notice of the suspension, the finding, and the reasons that support the finding; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#B(2)">(2)</span> An opportunity to be heard.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C">C.</span> The Secretary may impose a directed plan of correction, limit testing, deny a permit renewal, or suspend or revoke a current permit if a permittee has:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(1)">(1)</span> Failed to meet the applicable standards and requirements set forth in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(1)(a)">(a)</span> Health-General Article, Title 17, Annotated Code of Maryland; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(1)(b)">(b)</span> <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01" title="Chapter 01 General">COMAR 10.10.01</a>—.08 and this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(2)">(2)</span> Conducted research on newborn infant blood-spot specimens within the Newborn Screening Program’s approval as required in <a class="internal-link " href="/us/md/exec/comar/10.10.13.15" title=".15 Test Blood-Spot Specimens — Use, Research, Storage, and Retention.">Regulation .15 of this chapter</a>; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(3)">(3)</span> Failed to pay the Department any fee required under this subtitle.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#D">D.</span> In addition to sanctions provided in §§A and C of this regulation, the Secretary may:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#D(1)">(1)</span> Impose any sanction provided in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08" title="Chapter 08 Medical Laboratories — Sanctions">COMAR 10.10.08</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#D(2)">(2)</span> Refer a person for criminal prosecution, as provided at Health-General Article, §17-216, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#E">E.</span> A person may have a hearing on the imposition of a sanction and an opportunity to respond to a sanction imposed by the Secretary under this regulation as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08.03" title=".03 Departmental Actions — Principal Sanctions.">COMAR 10.10.08.03</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#F">F.</span> Except as provided in §§A and B of this regulation, before the Secretary denies, suspends, or revokes a permit, the Secretary shall give the applicant or permittee notice of the action and an opportunity to be heard.</p>
                <hr class="section-separator" aria-hidden="true"/>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.10.12" aria-label="Chapter 12 Medical Laboratories — Public Health HIV Testing Programs">
                <div class="h__ui">Previous</div>
                <span>Chapter 12 Medical Laboratories — Public Health HIV Testing Programs</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.11" aria-label="Subtitle 11 MATERNAL AND CHILD HEALTH">
                <div class="h__ui">Next</div>
                <span>Subtitle 11 MATERNAL AND CHILD HEALTH</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
